
Please try another search
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Joanna C. Horobin | 66 | 2019 | Independent Director |
Arthur S. Kirsch | 69 | 2016 | Independent Director |
Stephen M. Bloch | 58 | 2009 | Independent Chairman |
Roger A. Jeffs | 60 | 2020 | CEO & Director |
Ramandeep Singh | 53 | 2018 | Independent Director |
Katherine Rielly-Gauvin | 61 | 2019 | Independent Director |
Damian deGoa | 46 | 2020 | Independent Director |
Paul B. Manning | 69 | 2020 | Independent Director |
David Edward Johnson | 42 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review